This Trial Is Definitely Newsworthy, As It’s The First Advancement In Cannabinoid Research For Treatment Of Ibs In Medical History.

Dr. Stuart Titus. “This trial is definitely newsworthy, as it’s the first advancement in cannabinoid research for treatment of IBS in medical history. We’re excited to see AXIM continually reaching milestones in its clinical development program.” IBS is the most common disorder diagnosed by Medical marijuana gastroenterologists and accounts for up to 12% of total visits to primary care providers, accounting for between 2.4 3.5 million annual physician visits in the United States alone. About Medical Marijuana, Inc. Our mission is to be the premier cannabis and hemp industry innovators, leveraging ourteam of professionals to source, evaluate and purchase value-added companies andproducts, while allowing them to keep their integrity and entrepreneurial spirit. We striveto create awareness within our industry, develop environmentally-friendly, economicallysustainable businesses, while increasing shareholder value. For details onMedicalMarijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com . Shop fordiscounted products.

To read more visit http://www.wsfa.com/story/34434441/cbs-new-york-features-medical-marijuana-inc-investment-axim-biotechs-flagship-cbd-chewing-gum-ibs-clinical-trial

Comments are closed.